2022 Human Augmentation Market Share, Size, Trends Report: Increasing Adoption of Wearable Augmentation Products and Increased Understanding of the Therapeutic Benefits – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Human Augmentation Market Share, Size, Trends By Product Type, By Functionality, By Application, By Region, Segment Forecast, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering. The global human augmentation market is expected to reach USD 725.25 billion by 2030 Increasing adoption of wearable augmentation products and increased understanding of the therapeutic … [Read more…]

Global Antithrombin Market to Reach $681 Million by 2027 at a 4.9% CAGR – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Antithrombin: Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. Global Antithrombin Market to Reach $681 Million by 2027 In the changed post COVID-19 business landscape, the global market for Antithrombin estimated at US$486.2 Million in the year 2020, is projected to reach a revised size of US$681 Million by 2027, … [Read more…]

Alberto Bona’s Exploit on the Class40 IBSA: Eighth at the Route Du Rhum

“A very nice but extremely hard regatta: I’ve been sailing without the main autopilot since day 1” POINTE-À-PITRE, Guadeloupe Island–(BUSINESS WIRE)–#IBSA–Thursday, November, 24, at 3:34:50 pm local time (8:34:50 Paris-Rome time) in Pointe-à-Pitre, Alberto Bona on the Class40 IBSA crossed the finish line of the twelfth edition of the Route du Rhum in eighth place. … [Read more…]

Global EPA+DHA Omega-3 Finished Products Report: Data for 2020 and 2021 with Forecasts Through 2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “The Global EPA+DHA Omega-3 Finished Products Report – Data for 2020 and 2021 with forecasts through 2023” report has been added to ResearchAndMarkets.com’s offering. The EPA and DHA omega-3 finished product market size reached US$47 billion in 2021. Growth remains strongest in developing markets in Asia, Africa, and the Middle East, leading the … [Read more…]

Mednow to Host Quarterly Conference Call on Tuesday November 29, 2022, at 8:30am EST on its Fourth-Quarter 2022 Financial Results

TORONTO–(BUSINESS WIRE)–Mednow Inc. (“Mednow” or the “Company”) (TSXV:MNOW), Canada’s on-demand virtual pharmacy, is pleased to announce the Company will be hosting its quarterly conference call on Tuesday November 29, 2022 at 8:30am EST. The conference call will cover its fourth-quarter 2022 financial results. During the call, the Mednow team will provide an update on Mednow’s … [Read more…]

Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2022. Corporate and Clinical Development Highlights Include: Complete Clearance of Cancer in a Patient Treated with … [Read more…]

2022 Polycystic Kidney Disease Drugs in Development Report: Featuring Angion Biomedica, ATLAS Molecular Pharma, Bristol-Myers Squibb and Camurus Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Polycystic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. This publisher’s latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease – Drugs In Development, 2022, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline … [Read more…]

Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection

— Immediately de-prioritizes poziotinib program, accelerates cost reductions, including 75% reduction in R&D related workforce — — Spectrum to explore strategic alternatives for the poziotinib program, including partnerships and business development opportunities — BOSTON–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced … [Read more…]

Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chronic Hepatitis Delta Virus (HDV) Infection – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering. This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also … [Read more…]

Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously

Iron Deficiency Day unites a strong international coalition raising awareness on the serious health impact of iron deficiency and iron deficiency anemia1 This year, the focus is on importance of early diagnosis and treatment in chronic heart failure patients ST. GALLEN, Switzerland–(BUSINESS WIRE)–Regulatory News: Tomorrow is Iron Deficiency Day. For the eighth consecutive year, CSL … [Read more…]